These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12970798)

  • 1. Thalidomide therapy induces response in relapsed mantle cell lymphoma.
    Damaj G; Lefrère F; Delarue R; Varet B; Furman R; Hermine O
    Leukemia; 2003 Sep; 17(9):1914-5. PubMed ID: 12970798
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report.
    Wilson EA; Jobanputra S; Jackson R; Parker AN; McQuaker IG
    Br J Haematol; 2002 Oct; 119(1):128-30. PubMed ID: 12358916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide for mantle cell lymphoma.
    Skarbnik AP; Goy AH
    Expert Rev Hematol; 2015 Jun; 8(3):257-64. PubMed ID: 25952533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
    Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
    Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the management of mantle cell lymphoma.
    Rivera-Rodriguez N; Cabanillas F
    Curr Opin Oncol; 2013 Nov; 25(6):716-21. PubMed ID: 24076580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
    Robinson KS; Williams ME; van der Jagt RH; Cohen P; Herst JA; Tulpule A; Schwartzberg LS; Lemieux B; Cheson BD
    J Clin Oncol; 2008 Sep; 26(27):4473-9. PubMed ID: 18626004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.
    Guglielmelli T; Bringhen S; Rrodhe S; Gay F; Cavallo F; Berruti A; Montefusco V; Piro E; Benevolo G; Petrucci MT; Caravita T; Offidani M; Corradini P; Boccadoro M; Saglio G; Palumbo A
    Eur J Cancer; 2011 Apr; 47(6):814-8. PubMed ID: 21334196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma.
    Houillier C; Choquet S; Touitou V; Martin-Duverneuil N; Navarro S; Mokhtari K; Soussain C; Hoang-Xuan K
    Neurology; 2015 Jan; 84(3):325-6. PubMed ID: 25527263
    [No Abstract]   [Full Text] [Related]  

  • 10. Haematological cancers: Lenalidomide--SPRINT to a new standard?
    Hutchinson L
    Nat Rev Clin Oncol; 2016 Apr; 13(4):204. PubMed ID: 26925960
    [No Abstract]   [Full Text] [Related]  

  • 11. Mantle cell lymphoma: the promise of new treatment options.
    Goy A; Kahl B
    Crit Rev Oncol Hematol; 2011 Oct; 80(1):69-86. PubMed ID: 21168343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.
    Dasanu CA; Reale MA; Bauer F
    Leuk Res; 2010 Jul; 34(7):e178-80. PubMed ID: 20079532
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy.
    Yi JH; Kim SJ; Ko YH; Kim WS
    Leuk Lymphoma; 2011 Feb; 52(2):317-20. PubMed ID: 21067447
    [No Abstract]   [Full Text] [Related]  

  • 14. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
    Steurer M; Spizzo G; Mitterer M; Gastl G
    Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide in small cell lung cancer: wrong drug or wrong disease?
    Rüegg C; Peters S
    J Natl Cancer Inst; 2009 Aug; 101(15):1034-5. PubMed ID: 19608998
    [No Abstract]   [Full Text] [Related]  

  • 16. Thalidomide for patients with recurrent lymphoma.
    Pro B; Younes A; Albitar M; Dang NH; Samaniego F; Romaguera J; McLaughlin P; Hagemeister FB; Rodriguez MA; Clemons M; Cabanillas F
    Cancer; 2004 Mar; 100(6):1186-9. PubMed ID: 15022285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of thalidomide in the treatment of multiple myeloma.
    Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH
    Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865
    [No Abstract]   [Full Text] [Related]  

  • 18. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
    Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
    Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
    J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL?
    Lenz G; Dreyling M
    Nat Clin Pract Oncol; 2005 Feb; 2(2):72-3. PubMed ID: 16264875
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.